Clinical trials: Cancer of Liver
Colorectal Carcinoma
Neoadjuvant Recombinant Vaccinia Virus for Metastatic Colorectal Cancer With Liver Resection
This is a neoadjuvant Phase 2a, open-label trial in patients with metastatic colorectal carcinoma who are undergoing a complete resection of the metastatic colorectal tumors in their liver.
- Trial name
- NCT01329809
- Testing
- Recombinant Vaccinia GM-CSF; RAC VAC GM-CSF (JX-594)
- Where
- Canada
- Volunteers
- 2 people
- Sponsor
- Jennerex Biotherapeutics
Cancer, Hepatocellular
A Study of Nivolumab and Ipilimumab and Nivolumab Alone in Combination With Trans-arterial ChemoEmbolization (TACE) in Participants With Intermediate Stage Liver Cancer
The purpose of this study is to evaluate the safety and tolerability of nivolumab with and without ipilimumab in combination with Trans-arterial ChemoEmbolization (TACE) to TACE alone in participants with intermediate liver…
- Trial name
- CheckMate 74W (NCT04340193)
- Testing
- nivolumab, ipilimumab, TACE
- Where
- 107 sites in United States, Australia and 17 more
- Volunteers
- 26 people
- Sponsor
- Bristol-Myers Squibb
Head and Neck Squamous Cell Carcinoma (HNSCC)
A Study to Test Whether Different Combinations of BI 765063, Ezabenlimab, Chemotherapy, Cetuximab, and BI 836880 Help People With Head and Neck Cancer or Liver Cancer
With an amendment of the protocol, this study is only open to adults with head and neck cancer. Previously also adults with liver cancer joined.
- Trial name
- NCT05249426
- Testing
- BI 765063, Ezabenlimab, BI 836880
- Where
- 25 sites in United States, France and 9 more
- Volunteers
- 48 people
- Sponsor
- Boehringer Ingelheim
Hepatocellular Carcinoma
A Trial of Lenvatinib Plus Pembrolizumab in Participants With Hepatocellular Carcinoma
This is an open-label Phase 1b study designed to evaluate the tolerability and safety of lenvatinib in combination with pembrolizumab in participants with hepatocellular carcinoma (HCC).
- Trial name
- NCT03006926
- Testing
- lenvatinib, pembrolizumab (200 mg)
- Where
- 26 sites in United States, France and 5 more
- Volunteers
- 104 people
- Sponsor
- Eisai Co., Ltd.
Hepatocellular Carcinoma
A Study of LY2157299 in Participants With Advanced Hepatocellular Carcinoma
The main purpose of this study is to evaluate the safety and effectiveness of the study drug known as LY2157299 in participants with hepatocellular carcinoma.
- Trial name
- NCT02178358
- Testing
- LY2157299, Sorafenib
- Where
- 16 sites in China, Hong Kong and 3 more
- Volunteers
- 132 people
- Sponsor
- Eli Lilly and Company
Colorectal Adenocarcinoma Metastatic in the Liver, Liver Ablation
International Study on Treatment of Patients With Metastatic Colorectal Liver Lesions Patients With IRE
Procedural data will be recorded from patients with liver metastases from colorectal cancer who have received at least one course of systemic chemotherapy and who have been assessed by an appropriately constituted MDT (or…
- Conditions
- Colorectal Adenocarcinoma Metastatic in the Liver, Liver Ablation, Liver Cancer, Adult
- Trial name
- LIVERMET-IRE (NCT07191548)
- Testing
- Irreversible Electroporation
- Where
- United Kingdom
- Volunteers
- 50 people
- Sponsor
- Angiodynamics, Inc.
Hepatocellular Carcinoma, Advanced Cancer
CVM-1118 in Combination With Nivolumab for Unresectable Advanced Hepatocellular Carcinoma
CVM-1118 is a new small molecule chemical entity being developed as a potential anti-cancer therapeutic by TaiRx, Inc. CVM-1118 is a potent anti-cancer agent in numerous human cancer cell lines.
- Trial name
- NCT05257590
- Testing
- Nivolumab Injection [Opdivo], CVM-1118
- Where
- 5 sites in Taiwan
- Volunteers
- 95 people
- Sponsor
- TaiRx, Inc.
Hepatocellular Carcinoma
Efficacy and Safety Study of TLC388 to Advanced Hepatocellular Carcinoma
The purpose of this study is to evaluate the safety and efficacy of TLC388 (Lipotecan) as a second line treatment in subjects with advanced Hepatocellular Carcinoma.
- Trial name
- NCT02267213
- Testing
- Lipotecan
- Where
- 12 sites in China, Taiwan
- Volunteers
- 29 people
- Sponsor
- Taiwan Liposome Company
Hepatocarcinoma, Hepatic Metastasis
Robotic Endomicroscopy to Better Define Resection Strategies Applied to Hepatic Surgery
This study aims at assessing the feasibility of Probe-based Confocal Laser Endomicroscopy (pCLE) during laparoscopic hepatic masses resection for intra-operative characterisation of hepatic masses and surgical margins assessment.
- Conditions
- Hepatocarcinoma, Hepatic Metastasis, Hepatic Tumor
- Trial name
- PERSEE (NCT03718078)
- Testing
- Confocal Laser Endomicroscopy
- Where
- France
- Volunteers
- 40 people
- Sponsor
- Mauna Kea Technologies
Hepatocellular Carcinoma
Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Participants With Advanced Hepatocellular Carcinoma (HCC) Who Have Not Received Previous Systemic Anticancer Therapy
This Phase 3 study evaluates the safety and efficacy of cabozantinib in combination with atezolizumab versus the standard of care sorafenib in adults with advanced hepatocellular carcinoma (HCC) who have not received previous…
- Trial name
- COSMIC-312 (NCT03755791)
- Testing
- Cabozantinib, Sorafenib, Atezolizumab
- Where
- 245 sites in United States, Argentina and 32 more
- Volunteers
- 837 people
- Sponsor
- Exelixis
Hepatocellular Carcinoma
Phase III Trans-Arterial Chemo-Embolization (TACE) Adjuvant HCC
The purpose of this study is to compare the Overall Survival (OS) of HCC patients who receive brivanib as adjuvant treatments to TACE therapy, with the OS of HCC patients who receive matched placebo with TACE therapy.
- Trial name
- BRISK TA (NCT00908752)
- Testing
- Brivanib, TACE Therapy
- Where
- 94 sites in United States, Argentina and 11 more
- Volunteers
- 734 people
- Sponsor
- Bristol-Myers Squibb
Liver Cancer
Feasibility of a Minimally Invasive Image-Guided Surgery System for Hepatic Procedures
This study was designed to confirm that the surgeon is able to perform surface registration of standard liver features used as landmarks during a scheduled laparoscopic liver procedure.
- Trial name
- NCT01237990
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Pathfinder Therapeutics
Hepatocellular Carcinoma
Ph 3 ADI-PEG 20 Versus Placebo in Subjects With Advanced Hepatocellular Carcinoma Who Have Failed Prior Systemic Therapy
This is a study of ADI-PEG 20 (pegylated arginine deiminase), an arginine degrading enzyme versus placebo in patients with hepatocellular carcinoma who have failed prior systemic treatment (chemotherapy).
- Trial name
- ADI-PEG 20 (NCT01287585)
- Testing
- ADI-PEG 20 (arginine deiminase formulated with polyethylene glycol), Best Supportive Care
- Where
- 73 sites in United States, China and 4 more
- Volunteers
- 636 people
- Sponsor
- Polaris Group
Hepatocellular Carcinoma
A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma
The primary objectives of Cohort A Phase 1b and exploratory expansion are to evaluate the safety and tolerability of TTI-101 orally administered as a single agent to participants with locally advanced or metastatic, and…
- Trial name
- NCT05440708
- Testing
- TTI-101, Pembrolizumab, Atezolizumab
- Where
- 21 sites in United States
- Volunteers
- 193 people
- Sponsor
- Tvardi Therapeutics, Incorporated
Lung Cancer, Colorectal Cancer
ProSight: A Multi-centre Interventional Study Evaluating MCED in Asymptomatic Population
This is a prospective, multi-centre interventional study evaluating the feasibility of blood-based multi-cancer early detection test in asymptomatic screening cohort.
- Conditions
- Lung Cancer, Colorectal Cancer, Liver Cancer, Grastic Cancer
- Trial name
- NCT06790355
- Testing
- multi-cancer early detection
- Where
- 4 sites in China
- Volunteers
- 2,527 people, healthy volunteers welcome
- Sponsor
- Shanghai Weihe Medical Laboratory Co., Ltd.
Hepatocellular Carcinoma, Hepatoma
A Study of Relatlimab in Combination With Nivolumab in Participants With Advanced Liver Cancer Who Have Never Been Treated With Immuno-oncology Therapy After Prior Treatment With Tyrosine Kinase Inhibitors
The purpose of this study is to evaluate the effectiveness and safety of relatlimab in combination with nivolumab in participants with advanced liver cancer who have never been treated with immuno-oncology therapy, after prior…
- Conditions
- Hepatocellular Carcinoma, Hepatoma, Liver Cancer, Adult, Liver Cell Carcinoma
- Trial name
- NCT04567615
- Testing
- Nivolumab, Relatlimab
- Where
- 65 sites in Argentina, Brazil and 15 more
- Volunteers
- 266 people
- Sponsor
- Bristol-Myers Squibb
Hepatocellular Carcinoma
Study of TAC-101 as Second Line Treatment in Patients With Advanced Hepatocellular Carcinoma Who Received Sorafenib as First Line Therapy
The purpose of this study is to determine whether TAC-101 as a second line therapy for participants who received Sorafenib as first line therapy is effective in slowing tumor activity in patients with advanced hepatocellular…
- Trial name
- NCT00687596
- Testing
- TAC-101
- Where
- Italy
- Volunteers
- 52 people
- Sponsor
- Taiho Oncology, Inc.
Hepatocellular Carcinoma
A Study of LY2181308 in Patients With Advanced Hepatocellular Carcinoma
The primary objective of this study is to estimate the time to progressive disease for patients with advanced hepatocellular cancer who receive LY2181308.
- Trial name
- NCT00415155
- Testing
- LY2181308
- Where
- 12 sites in United States, France and 2 more
- Volunteers
- 60 people
- Sponsor
- Eli Lilly and Company
Cancer, Malignancy
A Study of ASN007 in Patients With Advanced Solid Tumors
The study is divided into two parts. The first part of the study will test various doses of ASN007 to find out the highest safe dose to test in five specific groups.
- Conditions
- Cancer, Malignancy, Neoplasia, Neoplasm
- Trial name
- NCT03415126
- Testing
- ASN007: ascending doses, ASN007 RD
- Where
- 5 sites in United States
- Volunteers
- 49 people
- Sponsor
- Asana BioSciences
Colorectal Cancer, Gastric Cancer
Study of BO-112 With Pembrolizumab for Colorectal or Gastric/GEJ Cancer With Liver Metastasis
This is an open, single arm, multicenter phase 2 trial in which BO-112 will be administered intratumorally in combination with intravenous pembrolizumab in patients with liver metastasis from colorectal, gastric or…
- Conditions
- Colorectal Cancer, Gastric Cancer, Oesophageal Cancer
- Trial name
- NCT04508140
- Testing
- Hepatic Biopsy, BO-112 with pembrolizumab
- Where
- 12 sites in Belgium, Italy and 1 more
- Volunteers
- 18 people
- Sponsor
- Highlight Therapeutics